In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the ...

AMR demands sustained commitment beyond conventional market incentives. It requires founders with deep personal conviction ...

The outcome of the study was just one setback reported by Vertex as it updated investors on its second-quarter results, ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

It's a pivotal moment for cell therapy. New trials, breakthrough data, major acquisitions and regulatory shifts are ...

The Gates Foundation is doubling down on its support for women's health research, pumping $2.5 billion between now and the ...

Around 240,000 people are expected to be offered Mounjaro over the next three years, according to NICE, which has recommended ...

Nalvee marks a return to the market for a dydrogesterone-only product after an absence of 17 years, and can be used in ...

Don't fall behind. Take a step toward becoming indispensable to your organization by attending our no-cost* LEAN Cell & Gene Boston Summit on Monday, September 22, conveniently planned just one day ...

Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more. #PharmaAI #RealTimeInsights ...

A former scientist at Google's DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time, setting up regulatory filings. The ...